Adverse events (number) ‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
Adverse events (proportion) ‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Serious adverse events · high‐risk surgical patients with acute calculous cholecystitis.
It is very uncertain whether intervention changes serious adverse events compared with control (very low certainty).
1 finding from 1 review
Serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus… compared with control (very low certainty).
1 finding from 1 review
Serious adverse events · adults with oesophageal varices
Band ligation probably leads to lower serious adverse events compared with no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events · people with hepatorenal syndrome
Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events · people with acute HBV infection
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Non‐serious adverse events · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1 finding from 1 review
Non‐serious adverse events · adults with oesophageal varices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes adverse events compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found